Evidence-based patient safety advisory: Malignant hyperthermia

Plastic and Reconstructive Surgery

Volumn 124, Issue 4S, 2009, Pages 68S-81S

  Gurunluoglu, Raffi ^a   Swanson, Jennifer A ^a   Haeck, Phillip C ^a  

^a DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBULATORY SURGERY; ANESTHESIA; EVIDENCE BASED MEDICINE; HUMAN; MALIGNANT HYPERTHERMIA; PATIENT SELECTION; PLASTIC SURGERY; REVIEW; SAFETY;

AMBULATORY SURGICAL PROCEDURES; ANESTHESIA; EVIDENCE-BASED MEDICINE; HUMANS; MALIGNANT HYPERTHERMIA; PATIENT SELECTION; RECONSTRUCTIVE SURGICAL PROCEDURES; SAFETY;

EID: 77957037939     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3181b54626     Document Type: Article

References (80)

1. Denborough MA, Lovell RRH. Anesthetic deaths in a family. Lancet 1960;2:45.
2. Greenhalgh T. How to Read a Paper: The Basics of Evidence-Based Medicine. 3rd ed. Oxford: Blackwell Publishing; 2006.
3. Lang TA, Secic M. How to Report Statistics in Medicine. 2nd ed. Philadelphia: American College of Physicians; 2006.
4. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM. 3rd ed. Philadelphia: Elsevier Churchill Livingstone; 2005.
5. Evidence-Based Medicine Working Group. Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice. Chicago: American Medical Association; 2002.
6. Center for Evidence Based Medicine. Levels of evidence and grades of recommendations. Available at: http://www.cebm.net/levels_of_evidence.asp#levels. Accessed April 30, 2007.
7. American Society of Plastic Surgeons. Scales for rating levels of evidence. Available at: http://www.plasticsurgery.org/Medical_Professionals/Health_Policy_and_Advocacy/Health_ Policy_Resources/Evidence-based_GuidelinesPractice_ Parameters/Description_and_Development_of_Evidence-based_Practice_Guidelines/ASPS_Evidence_Rating_Scales. html. Accessed February 4, 2009.
8. AmericanSocietyofPlasticSurgeons.Scaleforgradingpractice recommendations. Available at: http://www.plasticsurgery.org/Medical_Professionals/Health_Policy_and_Advocacy/ Health_Policy_Resources/Evidence-based_GuidelinesPractice_ Parameters/Description_and_Development_of_Evidence-based_Practice_Guidelines/ASPS_Grade_Recommendation_ Scale.html. Accessed February 4, 2009.
9. Adamson PA, Dahiya R, Litner J, Vosu H. Malignant hyperthermia: Successful management in a private surgery centre. J Otolaryngol. 2006;35:186-189.
10. Allen GC, Brubaker CL. Human malignant hyperthermia associated with desflurane anesthesia. Anesth Analg. 1998;86: 1328-1331.
11. Shulman M, Braverman B, Ivankovich A, Gronert G. Sevoflurane triggers malignant hyperthermia in swine. Anesthesiology 1981;54:259-260.
12. Gronert GA. Malignant hyperthermia. Anesthesiology 1980; 53:395-423.
13. Gallant EM, Gronert GA, Taylor SR. Cellular membrane potentials and contractile threshold in mammalian skeletal muscle susceptible to malignant hyperthermia. Neurosci Lett. 1982;28:181-186.
14. Gronert GA, Pessah IN, Muldoon SM, Tautz TJ. Malignant hyperthermia. In: Miller RD, ed. Miller's Anesthesia. Vol. 1, 6th ed. Philadelphia: Elsevier Churchill Livingstone; 2008:1169-1190.
15. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat. 2000;15:410-417.
16. Ibarra MC, Wu S, Murayama K, et al. Malignant hyperthermia in Japan: Mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006;104:1146-1154.
17. Robinson RL, Brooks C, Brown S, et al. RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes. Hum Mutat. 2002;20:88-97.
18. Monnier N, Procaccio V, Stieglitz P, Lunardi J. Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 1997;60:1316-1325.
19. Monaghan A, Hindle I. Malignant hyperpyrexia in oral surgery: Case report and literature review. Br J Oral Maxillofac Surg. 1994;32:190-193.
20. King JO, Denborough MA, Zapf PW. Inheritance of malignant hyperpyrexia. Lancet 1972;1:365-370.
21. Jungbluth H. Central core disease. Orphanet J Rare Dis. 2007; 2:25.
22. Jungbluth H. Multi-minicore Disease. Orphanet J Rare Dis. 2007;2:31.
23. Larach MG, Rosenberg H, Gronert G, Allen GC. Hyperkale-mic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin Pediatr (Phila.) 1997;36:9-16.
24. Murray C, Sasaki SS, Berg D. Local anesthesia and malignant hyperthermia: Review of the literature and recommendations for the dermatologic surgeon. Dermatol Surg. 1999;25: 626-630.
25. Haas DA, Young ER, Harper DG. Malignant hyperthermia and the general dentist: current recommendations. J Can Dent Assoc. 1992;58:28-33.
26. Chang CY, Scher RL. Malignant hyperthermia and the oto-laryngologist. Ear Nose Throat J. 2003;82:433-436.
27. Topel DG, Bicknell EJ, Preston KS, Christian LL, Matsushima CY. Porcine stress syndrome. Mod Vet Pract 1968;49:40-60.
28. Bendahan D, Kozak-Ribbens G, Confort-Gouny S, et al. A noninvasive investigation of muscle energetics supports similarities between exertional heat stroke and malignant hyperthermia. Anesth Analg. 2001;93:683-689.
29. Hackl W, Winkler M, Mauritz W, Sporn P, Steinbereithner K. Muscle biopsy for diagnosis of malignant hyperthermia susceptibility in two patients with severe exercise-induced my-olysis. Br J Anaesth. 1991;66:138-140.
30. Hopkins PM. Malignant hyperthermia: Advances in clinical management and diagnosis. Br J Anaesth. 2000;85:118-128.
31. Durham WJ, Racena-Parks P, Long C, et al. RyR1 S-nitrosy-lation underlies environmental heat stroke and sudden death in Y522S RyR1 knockin mice. Cell 2008;133:53-65.
32. Bryson GL, Chung F, Cox R, et al. Patient selection in ambulatory anesthesia: An evidence-based review. Part II. Can J Anaesth. 2004;51:782-794.
33. Rosenberg H, Davis M, James D, Pollock N, Stowell K. Malignant hyperthermia. Orphanet J Rare Dis. 2007;2:21.
34. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg. 1989;69:511-515.
35. Litman RS, Rosenberg H. Malignant hyperthermia: Update on susceptibility testing. JAMA. 2005;293:2918-2924.
36. Rosenberg H, Antognini JF, Muldoon S. Testing for malignant hyperthermia. Anesthesiology 2002;96:232-237.
37. Ording H, Brancadoro V, Cozzolino S, et al. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: Results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. Acta Anaesthesiol Scand. 1997;41:955-966.
38. Allen GC, Larach MG, Kunselman AR. The sensitivity and specificity of the caffeine-halothane contracture test: A report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology 1998;88:579-588.
39. Malignant Hyperthermia Association of the United States. MH muscle biopsy test centers page. Available at: http://www.mhaus.org/index.cfm/fuseaction/Content.Display/PagePK/BiopsyTestCenter.cfm. Accessed May 24, 2008.
40. Sei Y, Sambuughin NN, Davis E, et al. Malignant hyperthermia in North America: genetic screening of the three hot spots in the type I ryanodine receptor gene. Anesthesiology 2004;101:824-830.
41. Robinson R, Hopkins P, Carsana A, et al. Several interacting genes influence the malignant hyperthermia phenotype. Hum Genet. 2003;112:217-218.
42. Robinson RL, Anetseder MJ, Brancadoro V, et al. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing? Eur J Hum Genet. 2003;11:342-348.
43. Urwyler A, Deufel T, McCarthy T, West S; European Malignant Hyperthermia Group. Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. Br J Anaesth. 2001;86:283-287.
44. Girard T, Treves S, Voronkov E, Siegemund M, Urwyler A. Molecular genetic testing for malignant hyperthermia susceptibility. Anesthesiology 2004;100:1076-1080.
45. Malignant Hyperthermia Association of the United States. Molecular genetics test. Available at: http://www.patients.mhaus.org/index.cfm/fuseaction/Content.Display/PagePK/ MolGenTestSites.cfm. Accessed June 3, 2008.
46. American Society of Anesthesiologists. Office-based anesthesia guidelines. Available at: http://www.asahq.org/Washington/oba.htm. Accessed June 3, 2008.
47. Rohrich RJ, White PF. Safety of outpatient surgery: Is mandatory accreditation of outpatient surgery centers enough? Plast Reconstr Surg. 2001;107:189-192.
48. American Society of Anesthesiologists. Office-based anesthesia: State statutes, regulations and guidelines. Available at: http://www.asahq.org/Washington/rulesregs.htm. Accessed-June 3, 2008.
49. Rohrich RJ. Patient safety first in plastic surgery. Plast Reconstr Surg. 2004;114:201-203.
50. Iverson RE; ASPS Task Force on Patient Safety in Office-Based Surgery Facilities . Patient safety in office-based surgery facilities: I. Procedures in the office-based surgery setting. Plast Reconstr Surg. 2002;110:1337-1342; discussion 1343-1346.
51. Iverson RE, Lynch DJ. Patient safety in office-based surgery facilities: II. Patient selection. Plast Reconstr Surg. 2002;110: 1785-1790; discussion 1791-1792.
52. Horton JB, Reece EM, Broughton G II, Janis JE, Thornton JF, Rohrich RJ. Patient safety in the office-based setting. Plast Reconstr Surg. 2006;117:61e-80e.
53. Byrd HS, Barton FE, Orenstein H, et al. Safety and efficacy in an accredited outpatient plastic surgery facility: A review of 5316 consecutive cases. Plast Reconstr Surg. 2003;112:636-641; discussion 642-646.
54. American Society of Anesthesiologists. AMA core principles for office-based surgery. Available at: http://www.asahq.org/Washington/coreprinciples.htm. Accessed June 3, 2008.
55. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wap-pler F. Dantrolene: A review of its pharmacology, therapeutic use and new developments. Anaesthesia 2004;59:364-373.
56. Wackym PA, Dubrow TJ, Abdul-Rasool I, Lesavoy MA. Malignant hyperthermia in plastic surgery. Plast Reconstr Surg. 1988;82:878-882.
57. Wedel DJ, Quinlan JG, Iaizzo PA. Clinical effects of intravenously administered dantrolene. Mayo Clin Proc. 1995;70:241-246.
58. Malignant Hyperthermia Association of the United States. The ABC's of managing malignant hyperthermia. Available at: http://www.mhaus.org/index.cfm/fuseaction/OnlineBrochures.Display/BrochurePK/BCD9151D-3048-709E-5A445BC0808B4767.cfm. Accessed November 5, 2008.
59. Carr AS, Lerman J, Cunliffe M, McLead ME, Britt BA. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy. Can J Anaesth. 1995; 42:281-286.
60. Hackl W, Mauritz W, Winkler M, Sporn P, Steinbereithner K. Anaesthesia in malignant hyperthermia-susceptible patients without dantrolene prophylaxis: A report of 30 cases. Acta Anaesthesiol Scand. 1990;34:534-537.
61. Malignant Hyperthermia Association of the United States. Emergency therapy for malignant hyperthermia. Available at: http://medical.mhaus.org/PubData/PDFs/treatmentposter.pdf. Accessed May 24, 2008.
62. Hoefflin SM, Bornstein JB, Gordon M. General anesthesia in an office-based plastic surgical facility: A report on more than 23,000 consecutive office-based procedures under general anesthesia with no significant anesthetic complications. Plast Reconstr Surg. 2001;107:243-251; discussion 252-257.
63. Baudendistel L, Goudsouzian N, Cote' C, Strafford M. End-tidal CO2 monitoring: Its use in the diagnosis and management of malignant hyperthermia. Anaesthesia 1984;39:1000-1003.
64. Harrison GG. Control of the malignant hyperpyrexic syndrome in MHS swine by dantrolene sodium. 1975. Br J Anaesth. 1998;81:626-629; discussion 625.
65. Kolb ME, Horne ML, Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56:254-262.
66. Paul-Pletzer K, Yamamoto T, Bhat M, et al. Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor. J Biol Chem. 2002;277:34918-34923.
67. Ikemoto N, Yamamoto T. Postulated role of inter-domain interaction within the ryanodine receptor in Ca(2) channel regulation. Trends Cardiovasc Med. 2000;10:310-316.
68. Yamamoto T, Ikemoto N. Spectroscopic monitoring of local conformational changes during the intramolecular domain-domain interaction of the ryanodine receptor. Biochemistry 2002;41:1492-1501.
69. Kobayashi S, Bannister ML, Gangopadhyay J, Hamada T, Parness J, Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem. 2005;280: 6580-6587.
70. Murayama T, Oba T, Kobayashi S, Ikemoto N, Ogawa I. Postulated role of interdomain interactions within the type 1 ryanodine receptor in the low gain of Ca2-induced Ca2 release activity of mammalian skeletal muscle sarcoplasmic reticulum. Am J Physiol. 2005;288:C1222-C1230.
71. Larach MG, Localio AR, Allen G, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994;80:771-779.
72. Sambuughin N, Sei Y, Gallagher K, et al. North American malignant hyperthermia population: Screening of the ryanodine receptor gene and identification of novel mutations. Anesthesiology 2001;95:594-599.
73. Anderson AA, Brown RL, Polster B, Pollock N, Stowell KM. Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia. Anesthesiology 2008;108:208-215.
74. Britt BA, Endrenyi L, Frodis W, Scott E, Kalow W. Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle. Can Anaesth Soc J. 1980;27: 12-15.
75. Reed SB, Strobel GE Jr. An in-vitro model of malignant hyperthermia: Differential effects of inhalation anesthetics on caffeine-induced muscle contractures. Anesthesiology 1978; 48:254-259.
76. Flewellen EH, Nelson TE. Masseter spasm induced by succinylcholine in children: Contracture testing for malignant hyperthermia. Report of six cases. Can Anaesth Soc J. 1982; 29:42-49.
77. Snoeck MM, Gielen MJ, Tangerman A, van Egmond J, Dirksen R. Contractures in skeletal muscle of malignant hyperthermia susceptible patients after in vitro exposure to sevoflurane. Acta Anaesthesiol Scand. 2000;44:334-337.
78. Gallant EM, Godt RE, Gronert GA. Mechanical properties of normal and malignant hyperthermia susceptible porcine muscle: Effects of halothane and other drugs. J Pharmacol Exp Ther. 1980;213:91-96.
79. Louis CF, Zualkernan K, Roghair T, Mickelson JR. The effects of volatile anesthetics on calcium regulation by malignant hyperthermia-susceptible sarcoplasmic reticulum. Anesthesiology 1992;77:114-125.
80. Nelson TE, Flewellen EH. Rationale for dantrolene vs. pro-cainamide for treatment of malignant hyperthermia. Anesthesiology 1979;50:118-122.